CLDX
Income statement / Annual
Last year (2023), Celldex Therapeutics, Inc.'s total revenue was $6.88 M,
an increase of 192.02% from the previous year.
In 2023, Celldex Therapeutics, Inc.'s net income was -$141.43 M.
See Celldex Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$6.88 M
|
$2.36 M
|
$4.65 M
|
$7.42 M
|
$3.57 M
|
$9.54 M
|
$12.74 M
|
$6.79 M
|
$5.48 M
|
$3.59 M
|
| Cost of Revenue |
$118.01 M |
$1.40 M |
$3.07 M |
$42.53 M |
$42.67 M |
$66.45 M |
$96.17 M |
$102.03 M |
$4.01 M |
$101.88 M |
| Gross Profit |
-$111.13 M |
$957,000.00 |
$1.58 M |
-$35.12 M |
-$39.10 M |
-$56.91 M |
-$83.43 M |
-$95.24 M |
$1.47 M |
-$98.30 M |
| Gross Profit Ratio |
-16.15 |
0.41 |
0.34 |
-4.73 |
-10.94 |
-5.97 |
-6.55 |
-14.03 |
0.27 |
-27.41 |
| Research and Development
Expenses |
$118.01 M
|
$82.26 M
|
$53.31 M
|
$42.53 M
|
$42.67 M
|
$66.45 M
|
$96.17 M
|
$102.73 M
|
$100.17 M
|
$104.38 M
|
| General & Administrative
Expenses |
$30.91 M
|
$27.20 M
|
$20.49 M
|
$14.46 M
|
$15.43 M
|
$19.27 M
|
$25.00 M
|
$35.98 M
|
$33.84 M
|
$20.62 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$30.91 M
|
$27.20 M
|
$20.49 M
|
$14.46 M
|
$15.43 M
|
$19.27 M
|
$25.00 M
|
$35.98 M
|
$33.84 M
|
$20.62 M
|
| Other Expenses |
-$105.51 M |
$90.34 M |
$55.38 M |
$54.02 M |
$42.71 M |
$224,000.00 |
$896,000.00 |
$997,000.00 |
$1.01 M |
$1.01 M |
| Operating Expenses |
$43.41 M |
$109.45 M |
$73.80 M |
$56.99 M |
$58.10 M |
$85.94 M |
$122.07 M |
$139.70 M |
$135.02 M |
$126.02 M |
| Cost And Expenses |
$161.43 M |
$109.45 M |
$73.80 M |
$56.99 M |
$58.10 M |
$85.94 M |
$122.07 M |
$139.70 M |
$135.02 M |
$126.02 M |
| Interest Income |
$13.11 M |
$0.00 |
$505,000.00 |
$2.41 M |
$4.15 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$151.09 M |
$15.97 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.01 M
|
$1.40 M
|
$3.07 M
|
$2.00 M
|
$4.86 M
|
$3.80 M
|
$5.31 M
|
$4.09 M
|
$1.01 M
|
$1.01 M
|
| EBITDA |
-$139.03 M
|
-$104.20 M
|
-$66.08 M
|
-$45.64 M
|
-$49.67 M
|
-$72.60 M
|
-$104.02 M
|
-$124.44 M
|
-$125.53 M
|
-$116.53 M
|
| EBITDA Ratio |
-20.2 |
-43.22 |
-14.53 |
-5.15 |
-16.28 |
-0.07 |
-7.54 |
-20.09 |
-23.88 |
-33.86 |
| Operating Income Ratio
|
-22.45
|
-48.89
|
-15.32
|
-8.54
|
-15.4
|
-16.4
|
-9.54
|
-19.59
|
-23.64
|
-34.14
|
| Total Other
Income/Expenses Net |
$13.11 M
|
$2.91 M
|
$505,000.00
|
$2.41 M
|
$4.15 M
|
$4.49 M
|
$4.21 M
|
$4.39 M
|
$2.34 M
|
$4.35 M
|
| Income Before Tax |
-$141.43 M |
-$112.33 M |
-$70.74 M |
-$60.95 M |
-$50.88 M |
-$151.95 M |
-$117.31 M |
-$128.53 M |
-$127.20 M |
-$118.08 M |
| Income Before Tax Ratio
|
-20.55
|
-47.66
|
-15.21
|
-8.22
|
-14.24
|
-15.93
|
-9.21
|
-18.94
|
-23.21
|
-32.93
|
| Income Tax Expense |
$0.00 |
$10.46 M |
-$227,000.00 |
-$1.17 M |
-$506,000.00 |
-$765,000.00 |
-$24.28 M |
-$8.77 M |
-$2.34 M |
-$4.35 M |
| Net Income |
-$141.43 M |
-$122.78 M |
-$70.51 M |
-$59.78 M |
-$50.37 M |
-$151.18 M |
-$93.03 M |
-$128.53 M |
-$127.20 M |
-$118.08 M |
| Net Income Ratio |
-20.55 |
-52.09 |
-15.16 |
-8.06 |
-14.1 |
-15.85 |
-7.3 |
-18.94 |
-23.21 |
-32.93 |
| EPS |
-2.92 |
-2.62 |
-1.64 |
-2.02 |
-3.47 |
-14.48 |
-10.86 |
-18.99 |
-19.66 |
-19.81 |
| EPS Diluted |
-2.92 |
-2.62 |
-1.64 |
-2.02 |
-3.47 |
-14.48 |
-10.86 |
-18.99 |
-19.66 |
-19.81 |
| Weighted Average Shares
Out |
$48.45 M
|
$46.89 M
|
$42.87 M
|
$29.64 M
|
$14.51 M
|
$10.44 M
|
$8.57 M
|
$6.77 M
|
$6.47 M
|
$5.96 M
|
| Weighted Average Shares
Out Diluted |
$48.45 M
|
$46.89 M
|
$42.87 M
|
$29.64 M
|
$14.51 M
|
$10.44 M
|
$8.57 M
|
$6.77 M
|
$6.47 M
|
$5.96 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
